Clinical Trials Logo
  1. Home
  2. Neonatal Seizure
  3. NCT06211192

What Are the Determinant Factors of Ceasing Anti-seizure Medication in Infants With Neonatal Seizures?

Neonatal Seizure Clinical Trial

Official title:
Evaluation of the Determinant Factors of Ceasing Anti-seizure Medication in Infants With Neonatal Seizures: A Single-center Retrospective Study

Clinical Trial Summary

The investigators aimed to determine the factors for ceasing anti-seizure medication in infants who experienced seizures during the neonatal period. This retrospective, single-center, descriptive study was conducted in Balıkesir between December 2020 and February 2023, and 157 neonates were recruited.

Clinical Trial Description

This retrospective, single-center, descriptive study was conducted at the Department of Paediatric Neurology between December 2020 and February 2023, and 157 neonates were recruited to determine the factors related to ceasing ASM treatment in infants at a follow-up 2 years. According to the International League Against Epilepsy (ILAE) classification of neonatal seizures and their etiology, patients who were diagnosed with such seizures and received anti-seizure medication within the first 28 days of life were followed until their ASM was ceased after they were discharged from the neonatal intensive care unit. Infants are defined as children aged younger than 12 months. During this stage of neuronal development, the central nervous system is more susceptible to the harmful effects of external factors. Consequently, the investigators have planned to evaluate the study's initial 12-month follow-up results for our group. Afterwards, the infants were divided into two groups: the first group consisted of infants who continued to receive ASM treatment after 12 months of age (referred to as "infants still on ASM after 12 months", n=69); the second group consisted of infants who had stopped ASM treatment before 12 months of age (referred to as "infants who had ceased ASM before 12 months", n=88). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06211192
Study type Observational
Source Balikesir University
Contact
Status Completed
Phase
Start date January 1, 2020
Completion date October 1, 2023
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05127070 - Evaluating the NeoTree in Malawi and Zimbabwe
Withdrawn NCT03602118 - Study to Evaluate Phenobarbital Sodium Injection for the Treatment of Neonatal Seizures Phase 3
Not yet recruiting NCT04831242 - Monitoring Key Activity and Physiology of Neonates in Intensive Care
Completed NCT01224457 - Effect of CYP2C9/CYP2C19 Polymorphism on Pharmacokinetics of Phenobarbital in Korean Neonatal Seizure Patients. N/A
Recruiting NCT05610085 - A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures Phase 2
Recruiting NCT05036395 - The Effect of AI-assisted cEEG Diagnosis on the Administration of Antiseizure Medication in Neonatal Seizures N/A
Withdrawn NCT04991779 - AI-assisted cEEG Diagnosis of Neonatal Seizures in Neonatal Intensive Care Unit
Recruiting NCT04337697 - Neonatal Seizure Registry - Developmental Functional EValuation
Withdrawn NCT03996317 - Maternal Hyperoxygenation for Intrapartum Fetal Heart Rate Tracing Abnormalities N/A
Active, not recruiting NCT06308185 - Neonatal Seizures: Semiology, Etiology, Therapy and Prognosis Correlations
Not yet recruiting NCT05257889 - Neonatal Seizures in NICU of Assuit University Children's Hospital
Not yet recruiting NCT03786497 - Protecting Brains and Saving Futures - the PBSF Protocol
Completed NCT01747863 - Prospective Research in Infants With Mild Encephalopathy N/A
Active, not recruiting NCT04259125 - Evaluating the Role of Inflammation in Neonatal Epileptogenesis
Recruiting NCT05361070 - Neonatal Seizure Registry, GEnetics of Post-Neonatal Epilepsy